Drugs /

testosterone enanthate

Back to Drugs List

Overview

NCI Definition [1]:
A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)

Clinical Trials

View Clinical Trials for testosterone enanthate

Testosterone enanthate has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating testosterone enanthate, 1 is phase 2 (1 open).

ATM Loss, ATM Mutation, and ATR Loss are the most frequent biomarker inclusion criteria for testosterone enanthate clinical trials.

Prostate adenocarcinoma is the most common disease being investigated in testosterone enanthate clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Testosterone Enanthate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating testosterone enanthate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
btg brand of testosterone enanthate, testate, testosterone enanthate, testo-enant, theramed brand of testosterone enanthate, testosterone enanthate [chemical/ingredient], testinon, androtardyl, andro la, delatestryl, everone, testosterone heptanoate, testosterone enanthate, primosteston, testosterone enanthate (substance), testosterone enantate, testosterone enanthate, testosterone heptylate, testosterone enanthate (product)
NCIT ID [1]:
C1247
SNOMED ID [1]:
C-A0503

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.